CD40LG and COVID-19: The study duration is 9 months and the intervention period is 90 days from the day of enrolment of the participant.<h4>Participants</h4>Patients of either sex between 18 to 60 years, ambulatory, willing to participate, with history (not more than 4 weeks) of positive RT-PCR for COVID-19 or IgM antibodies positivity for SARS CoV-2, but having negative RT-PCR for COVID-19 at the time of screening will be considered eligible for enrolment in the study.